Dimethyl fumarate attenuates bile acid retention and liver fibrosis in a mouse model of cholestasis
Language English Country United States Media print-electronic
Document type Journal Article
Grant support
UNCE24/MED/008
Grantová Agentura, Univerzita Karlova (GA UK)
SVV-2023-260656
Grantová Agentura, Univerzita Karlova (GA UK)
SVV-260663
Grantová Agentura, Univerzita Karlova (GA UK)
CZ.02.01.01/00/22_008/0004607
EC | European Regional Development Fund (ERDF)
22-05167S
Grantová Agentura České Republiky (GAČR)
GAUK 116824
Grantová Agentura, Univerzita Karlova (GA UK)
R01DK130884
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
DZRO-FVZ22-ZHN II
Ministerstvo Obrany České Republiky (MOČR)
- Keywords
- 3, 4-dihydrocollidine (DDC), 5-diethoxycarbonyl-1, bile acids, cholestasis, dimethyl fumarate, liver fibrosis,
- MeSH
- Cholestasis * drug therapy metabolism chemically induced MeSH
- Dimethyl Fumarate * pharmacology therapeutic use MeSH
- Liver Cirrhosis * metabolism drug therapy pathology etiology MeSH
- Hepatic Stellate Cells drug effects metabolism MeSH
- Liver * metabolism drug effects pathology MeSH
- Disease Models, Animal MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Bile Acids and Salts * metabolism MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Dimethyl Fumarate * MeSH
- Bile Acids and Salts * MeSH
Cholestatic liver diseases are characterized by intrahepatic accumulation of bile acids (BAs), exacerbating liver inflammation, and fibrosis. Dimethyl fumarate (DMF) is a clinically approved anti-inflammatory drug that demonstrated protective effects in several experimental models of liver injury. Still, its effect on BA homeostasis and liver fibrosis has not been thoroughly studied. Herein, we hypothesized that DMF could improve BA homeostasis and mitigate the progression of cholestasis-induced liver fibrosis. The DMF was administered to mice with 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induced cholestasis for 4 wk. The content of individual BAs in the plasma, liver, bile, intestine, and feces was measured using the LC-MS method alongside the analysis of liver phenotype and related executive and regulatory pathways. The DMF slowed down the progression of DDC-induced liver fibrosis by suppressing hepatic stellate cell and macrophage activation and by reducing c-Jun N-terminal kinase phosphorylation. Notably, DMF reduced BA cumulation in the plasma and liver of cholestatic mice by increasing BA fecal excretion via their reduced Bacteroidetes phyla-mediated deconjugation in the intestine. In addition, DMF was identified as the antagonist of the mouse farnesoid X receptor in enterocytes. In conclusion, DMF alleviates DDC-induced cholestatic liver injury through pleiotropic action leading to significant anti-inflammatory and antifibrotic activity of the agent. In addition, DMF mitigates BA retention in the liver and plasma by increasing their fecal excretion in cholestatic mice. These findings suggest that DMF warrants further investigation as a potential therapeutic agent for human chronic fibrosing cholestatic liver disorders.NEW & NOTEWORTHY Chronic cholestatic cholangiopathies present a therapeutic challenge due to their complex pathophysiology, where the accumulation of bile acids plays a crucial role. In this study, we found that dimethyl fumarate attenuated cholestatic liver damage in a murine model through its significant anti-inflammatory and antifibrotic activity supported by reduced bile acid accumulation in the plasma and liver via their increased fecal excretion.
References provided by Crossref.org
